Echinocandine bei invasiven Candida-Infektionen

  title={Echinocandine bei invasiven Candida-Infektionen},
  author={Andreas Gl{\"o}ckner and Oliver Andreas Cornely},
  journal={Medizinische Klinik},
ZusammenfassungInvasive Mykosen werden auf der Intensivstation hauptsächlich durch Arten der Gattung Candida verursacht und treten zumeist als Candidämie auf. Trotz verbesserter therapeutischer Möglichkeiten in den letzten 2 Jahrzehnten ist die Letalität der invasiven Candidiasis mit 20–50% weiterhin hoch. Seit Anfang des Jahrtausends steht mit den Echinocandinen eine weitere Klasse von Antimykotika zur Verfügung, deren Wirkspektrum die klinisch relevanten Spezies von Candida und Aspergillus… Expand
2 Citations
Micafungin im Vergleich zu Caspofungin bei der Behandlung von invasiven Candida-Infektionen: Eine Kosteneffektivitätsanalyse für Deutschland
Both lower costs and higher effectiveness show micafungin to be more cost-effective than caspofungin for the treatment of systemic candida infections in Germany. Expand
Pharmacotherapy of yeast infections
This review summarizes the current knowledge about the use of the main antifungals for treating infections caused by the yeast species with the most significant clinical relevance, including the susceptibility profiles exhibited by these species in vitro. Expand


The Echinocandins
The clinical response to combination therapy has been variable; however, the mortality rate appears to be lower with combination therapy than monotherapy, and large controlled trials are needed to determine the role of combination therapy for invasive aspergillosis. Expand
A comparative evaluation of properties and clinical efficacy of the echinocandins
Combination therapy with echinocandins plus other licensed antifungal therapy shows promise in treating invasive aspergillosis. Expand
In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
The echinocandins appear to have variable and species dependent fungistatic activity for the dematiaceous fungi, but all agents have poor or no activity against most isolates of Scedosporium prolificans. Expand
Micafungin: A New Echinocandin Antifungal
Micafungin's efficacy against Candida sp, coupled with its overall safety and drug interaction profiles, makes it an attractive option in the treatment against esophageal candidiasis and prophylaxis against invasive candidal infections. Expand
Echinocandin antifungals: review and update
  • V. Morrison
  • Medicine
  • Expert review of anti-infective therapy
  • 2006
The echinocandins are an important addition to the antifungal armamentarium in the treatment of fungal infections in both immunocompromised patients and those with normal immunity. Expand
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
Micafungin was as effective as--and caused fewer adverse events than--liposomal amphotericin B as first-line treatment of candidaemia and invasive candidosis. Expand
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial
Voriconazole was as effective as the regimen of amphotericin B followed by fluconazole in the treatment of candidaemia in non-neutropenic patients, and with fewer toxic effects. Expand
The Antifungal Echinocandin Caspofungin Acetate Kills Growing Cells of Aspergillus fumigatus In Vitro
D dye-staining patterns illustrate that the cells at the active centers for new cell wall synthesis within A. fumigatus hyphae are killed when they are exposed to caspofungin, an antifungal antibiotic that inhibits synthesis of 1,3-β-d-glucan, an essential component of the fungal cell wall. Expand
Caspofungin for the treatment of less common forms of invasive candidiasis.
In deep-seated invasive candidiasis, including peritonitis, abdominal abscesses, CDC and arthritis, caspofungin was effective and safe at regular doses and up to 100 mg daily. Expand
Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp
The new echinocandin micafungin has excellent in vitro activity against 315 invasive clinical isolates of fluconazole-resistant Candida species obtained from geographically diverse medical centers between 2001 and 2004 and may prove useful in the treatment of infections due to azole- resistant Candida. Expand